UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~February 17~~ April 12, ~~2019~~2021

IMMUNE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-36602

52-1841431

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1 Bridge Plaza North, Suite 270, Fort Lee, NJ		07024
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (201) 464-2677

(Former name or former address, if changed since last report) N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

¨Securities registered ~~Soliciting material~~ pursuant to ~~Rule~~Section ~~14a-~~12(b) ~~under~~of the ~~Exchange~~ Act ~~(17 CFR 240.14a-12)~~:

¨Title ~~Pre-commencement~~of ~~communications~~each ~~pursuant~~class toTrading ~~Rule 14d-2~~symbol(bs) ~~under~~Name ~~the~~of ~~Exchange~~each ~~Act~~exchange ~~(17~~on ~~CFR~~which ~~240.14d-2(b))~~registered Common stock IMNPQ OTC

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company	¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.	¨

Emerging growth company [ ]

~~Item~~If ~~1.03~~an ~~Bankruptcy~~emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or ~~Receivership~~revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

On February 17, 2019, Immune Pharmaceuticals Inc. (the “Company”) filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code, 11 U.S.C. §§ 101, et seq., in the United States Bankruptcy Court for the District of New Jersey, captioned Immune Pharmaceuticals, Inc., et al., Case No.: 19-13273 (VFP).

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On April ~~March~~12, 62021, ~~2019~~Adeel Ahmed-Daudpota, ~~Tony~~age ~~Fiorino~~34, ~~resigned~~ has been appointed as the President and Interim Chief Executive Officer of the ~~Company.~~Immune ~~Dr. Fiorino will continue as a member of the Company’s~~Pharmaceuticals ~~Board of Directors. Dr. Fiorino’s resignation was not due~~ to ~~any~~fill ~~disagreement related to~~ the ~~Company’s~~vacancy ~~operations, policies~~that orresulted ~~practices,~~from ~~financial~~the ~~status~~company orentering ~~financial~~into ~~statements~~chapter 7.

Mr. ~~Gary~~Ahmed-Daudpota H.is ~~Rabin,~~an ~~age~~investment 53banker, ~~has~~predominantly ~~been~~specializing ~~appointed~~in asM&A, ~~the~~restructurings, ~~President~~ and ~~Interim~~Special ~~Chief~~Situations. ~~Executive~~In ~~Officer~~connection with ofhis ~~the~~appointment ~~Company~~ to ~~succeed~~the ~~Dr.~~board ~~Fiorino. Mr.~~of ~~Rabin~~Immune ~~has~~Pharmaceuticals ~~also~~as ~~been~~Interim ~~elected~~CEO, toMr ~~the Company~~Daudpota’s ~~Board~~role ofWill ~~Directors~~entail toproviding ~~fill~~ the ~~vacancy resulting from Dr. Cameron Durrant~~company’s ~~resignation~~shareholders asoptions ato ~~member~~continue oftrading ~~the~~and ~~Board~~for ofidentifying ~~Directors~~and inmerging ~~September~~with ~~2018~~another viable pharmaceutical business.

~~Mr.~~The appointment ~~Rabin has served~~ as asuch ~~consultant~~carries ~~to the~~no ~~Company~~compensation ~~since~~and ~~October~~does ~~2018.~~not ~~Since~~cover ~~November~~any ~~2014, Mr~~expenses. ~~Rabin~~This ~~has~~is ~~been~~subject ~~the managing member of Vine Holdings Group LLC, a restructuring and financial advisory firm. From December 2007~~ to ~~January~~change 2014, Mr. Rabin held a number of positions with Advanced Cell Technology, Inc., including director, Interim Chief Executive Officer and Chairman of the Board and Chief Executive Officer and Chairman of the Board. Mr. Rabin has a 32post-year career in finance, including as a portfolio manager for hedge funds investing in the technology, media and telecommunications industries and as a media and telecommunications investment banker, primarily focused on investment management and capital raising targeting small-cap and emerging growth companiesmerger.

~~In connection with his employment as the~~The ~~Company’s~~proposed ~~President~~merger ~~and~~is ~~Interim~~intended ~~Chief~~to ~~Executive~~protect ~~Officer,~~existing ~~the~~shareholder ~~Company~~interest ~~has entered into an employment agreement with Mr. Rabin, dated March 7, 2019 (the “Employment Agreement”), which provides for Mr. Rabin’s appointment as President~~ and ~~Interim~~ ~~Chief~~provide ~~Executive Officer for~~ a ~~term~~private ~~ending~~pharmaceutical oncompany ~~June~~a 7,public ~~2019.~~company ~~In the Employment Agreement, the Company agreed to pay Mr. Rabin $11,000~~ and ~~to pay Mr. Rabin an additional $4,000 on each of April 7, May 7 and June 7, 2019. The Company also agreed to reimburse~~ ~~Mr.~~large ~~Rabin~~shareholder ~~for~~base ~~his reasonable out-of-pocket or associate expenses incurred in connection with his service~~ to ~~the~~raise ~~Company.~~additional ~~In the Employment Agreement, Mr~~capital. ~~Rabin also agreed to customary confidentiality, non-solicitation and invention covenants.~~

~~The~~- ~~foregoing~~2 summary of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the Employment Agreement, a copy of which is filed herewith as Exhibit 10.1 and incorporated by reference herein in its entirety.-

~~There~~Item ~~are no arrangements or understandings between Mr~~8. ~~Rabin and any other persons pursuant to which he was elected as President and Interim Chief Executive Officer~~01. ~~There~~ ~~are~~Other also no family relationships between Mr. Rabin and any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.Events

OnMr Daudpota ~~March~~effective 7,immediately ~~2019,~~upon ~~the~~appointment ~~Company~~shall ~~issued~~be ~~a press~~responsible ~~release~~for ~~announcing~~updating ~~Dr.~~the ~~Fiorino~~company’s ~~resignation~~filings asto anbring ~~officer of~~ the ~~Company~~company ~~and the appointment of Mr. Rabin as his successor~~up ~~and~~to ~~his~~date ~~election~~with asits aregulatory ~~director~~requirements, ofIn ~~the~~addition ~~Company~~Mr. ADaudpota ~~copy~~is ofresponsible ~~the~~for ~~press~~providing ~~release~~a isviable ~~filed~~merger ~~herewith~~candidate ~~as Exhibit 10.2~~ and ~~incorporated by~~overseeing ~~reference~~the ~~herein~~merger inwith ~~its~~a ~~entirety~~new entity.

~~-2-~~Mr Daudpota hereby notifies the market that a merger is expected to take place within the coming weeks that will ensure the common stock holders will be protected from discontinuation of trading or loss of public equity.

~~Item~~Mr Daudpota ~~9.01.~~has ~~Financial~~secured ~~Statements~~the full support of United General LTD a UK investment firm and ~~Exhibits~~liquidity provider, Where he also he holds a board position.

The proposed merger plan will separate the Immune Pharmaceuticals LLC (dIn chapter 7) ~~Exhibits~~into the surviving entity that will not be subject to chapter 7 bankruptcy.

Exhibit Number		Description
10.1		Employment Agreement, dated March 7, 2019, by and between Immune Pharmaceuticals Inc. and Gary H. Rabin
10.2		Press release dated March 7, 2019

Holders of common stock under this structure will retain a shareholding in the surviving public company and will be afforded as such shareholder rights in the new operating pharmaceutical company post-merger.

~~-3-~~Upon completion of the merger, we will appoint a new board and apply to have the bankruptcy status lifted from Finra.

- 3 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

IMMUNE PHARMACEUTICALS INC. By: /s/ ~~Gary~~Adeel H.Ahmed-Daudpota ~~Rabin~~ Name: ~~Gary~~Adeel H.Ahmed-Daudpota ~~Rabin~~ Title: President and Interim Chief Executive Officer

Date: April ~~March 8~~12, ~~2019~~2021

- 4 -

Filing Compare · IMMUNE PHARMACEUTICALS INC